Low dose of esketamine after childbirth helps mothers at risk of depression
The Brown University Psychopharmacology Update August 1, 2024 DOI: 10.1002/pu.31189 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Population | Women with prenatal depressive symptoms |
| Intervention | Esketamine |
| Dose | single low dose |
| Duration | 42 days postpartum |
| Topics | Depression Esketamine |
| Key points | Women with prenatal depressive symptoms who received a single low dose of esketamine shortly after childbirth showed a substantially lower incidence of a major depressive episode at 42 days postpartum than those receiving placebo. Neuropsychiatric adverse events occurred more frequently with esketamine, but no severe adverse events were reported. |
Abstract
Women with prenatal depressive symptoms who received a single low dose of esketamine shortly after childbirth showed a substantially lower incidence of a major depressive episode at 42 days postpartum than women receiving placebo, a new study has found. Neuropsychiatric adverse events occurred more frequently in the esketamine group, but no severe adverse events were reported.